Big Multiple Sclerosis BreakthroughPhase 1 trial safely resets patients’ immune systems, reduces attack on myelin protein.
Combined Immunotherapy Shows Promising Results Against Advanced MelanomaCombining two cancer immunotherapy drugs in patients with advanced melanoma produced rates of tumor regression that appeared greater than in prior trials with either drug alone.
NIH to Fund Clinical Research Network on Antibacterial ResistanceResearchers at Duke University will lead the initiative.
Combined Immunotherapy Shows Promising Results Against Advanced MelanomaTumor regression rates are produced by combining two cancer immunotherapy drugs.
Promising Drug Prevents Cancer Cells from Shutting Down Immune SystemData from Phase 1 trial presented at the 2013 annual meeting of the ASCO in Chicago.
Double Dose of Tamiflu Offers No Added Benefit in Severe FluEarly treatment with Tamiflu is beneficial for patients with uncomplicated flu infection.
Enzyme-Activating Antibodies Revealed As Marker for Severe Rheumatoid ArthritisFinding could lead to earlier diagnosis and new, more aggressive treatment for worst cases.
Researchers Identify Novel Class of Drugs for Prostate CancersA new study on prostate cancer describes a novel class of drugs that interrupts critical signaling needed for prostate cancer cells to grow.
Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute CollaboratePartnership will accelerate the pace of discovery and innovation in Biomedical Sciences.
First Patient Dosed in the Phase I/II Study of UC1010 for PMDD PatientsFirst patient has been dosed with UC1010 in a double-blind, multicenter study.
